USANA Health Sciences Stock Price, News & Analysis (NYSE:USNA)

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

USANA Health Sciences announced that its Board of Directors has initiated a share repurchase plan on Tuesday, October 23rd 2018, which authorizes the company to buyback $150,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 5.9% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's board of directors believes its stock is undervalued.

USANA Health Sciences, Inc. (NYSE:USNA) released its earnings results on Tuesday, July, 23rd. The company reported $0.91 earnings per share for the quarter, missing the consensus estimate of $0.93 by $0.02. The company had revenue of $256 million for the quarter, compared to the consensus estimate of $254.66 million. USANA Health Sciences had a return on equity of 27.22% and a net margin of 9.68%. The firm's revenue was down 15.1% compared to the same quarter last year. During the same period in the previous year, the company posted $1.36 EPS. View USANA Health Sciences' Earnings History.

USANA Health Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, October 22nd 2019. View Earnings Estimates for USANA Health Sciences.

USANA Health Sciences issued an update on its FY19 earnings guidance on Tuesday, July, 23rd. The company provided EPS guidance of $3.70-4.10 for the period, compared to the Thomson Reuters consensus estimate of $3.89. The company issued revenue guidance of $1.02-1.06 billion, compared to the consensus revenue estimate of $1.06 billion.

4 Wall Street analysts have issued 12 month price targets for USANA Health Sciences' shares. Their forecasts range from $65.00 to $75.00. On average, they expect USANA Health Sciences' share price to reach $70.00 in the next twelve months. This suggests a possible upside of 3.0% from the stock's current price. View Analyst Price Targets for USANA Health Sciences.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for USANA Health Sciences.

Headlines about USNA stock have been trending somewhat negative on Tuesday, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. USANA Health Sciences earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for USANA Health Sciences.

USANA Health Sciences saw a increase in short interest in August. As of August 31st, there was short interest totalling 1,563,200 shares, an increase of 14.9% from the July 31st total of 1,360,900 shares. Based on an average daily trading volume, of 361,600 shares, the days-to-cover ratio is currently 4.3 days. Approximately 12.2% of the company's shares are sold short. View USANA Health Sciences' Current Options Chain.

Some companies that are related to USANA Health Sciences include STADA Arzneimittel (STDAF), Aurora Cannabis (ACB), Cronos Group (CRON), Tilray (TLRY), Sundial Growers (SNDL), Canopy Rivers (RIV), Chromadex (CDXC), Foamix Pharmaceuticals (FOMX), True Drinks (TRUU), Mediwound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), FitLife Brands (FTLF) and GLG Life Tech (GLGLF).

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include Tableau Software (DATA), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Allergan (AGN), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), Sarepta Therapeutics (SRPT), United Therapeutics (UTHR) and Vertex Pharmaceuticals (VRTX).

USANA Health Sciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.34%), Renaissance Technologies LLC (8.03%), Vanguard Group Inc. (6.45%), Acadian Asset Management LLC (3.49%), Morgan Stanley (1.34%) and D. E. Shaw & Co. Inc. (1.22%). Company insiders that own USANA Health Sciences stock include Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott, Robert Auciaux and Walter Noot. View Institutional Ownership Trends for USANA Health Sciences.

USNA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Robeco Institutional Asset Management B.V., Prudential Financial Inc., JPMorgan Chase & Co., AQR Capital Management LLC, Bank of America Corp DE, Wells Fargo & Company MN and Vanguard Group Inc.. Company insiders that have sold USANA Health Sciences company stock in the last year include Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, Joshua Foukas, Kevin Guest, Myron W Wentz, Robert Auciaux and Walter Noot. View Insider Buying and Selling for USANA Health Sciences.

USNA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Nuveen Asset Management LLC, Schroder Investment Management Group, Wasatch Advisors Inc., Clark Estates Inc. NY, Invesco Ltd., D. E. Shaw & Co. Inc. and Boston Partners. Company insiders that have bought USANA Health Sciences stock in the last two years include Global Ltd Gull and Myron W Wentz. View Insider Buying and Selling for USANA Health Sciences.

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of USNA stock can currently be purchased for approximately $67.95.

USANA Health Sciences has a market capitalization of $1.51 billion and generates $1.19 billion in revenue each year. The company earns $126.22 million in net income (profit) each year or $5.16 on an earnings per share basis. USANA Health Sciences employs 1,911 workers across the globe.View Additional Information About USANA Health Sciences.

The official website for USANA Health Sciences is http://www.usana.com/.

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at 801-954-7100 or via email at [email protected]